Intellia Therapeutics (NTLA) Free Cash Flow (2015 - 2026)
Intellia Therapeutics (NTLA) posted quarterly Free Cash Flow of -$117.3 million for Q1 2026, up 21.25% year-over-year from -$96.8 million in Q1 2025, and down 69.06% quarter-over-quarter from -$69.4 million in Q4 2025.
Intellia Therapeutics (NTLA) Free Cash Flow (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Free Cash Flow for 12 consecutive years, with -$117.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow rose 21.25% year-over-year to -$117.3 million; the TTM figure through Mar 2026 stood at -$364.2 million (up 2.96% YoY), while the FY2025 annual figure was -$395.9 million, down 13.28% from the prior year.
- Free Cash Flow fell to -$117.3 million in Q1 2026 per NTLA's latest filing, from -$69.4 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$56.3 million in Q2 2024 and bottomed at -$149.0 million in Q1 2025.
- Historically, Free Cash Flow has averaged -$93.7 million across 5 years, with a median of -$85.4 million in 2024.
- Annual changes were most pronounced in 2024 — Free Cash Flow surged 40.68% — and 2025, when it tumbled 76.77%.
- Intellia Therapeutics' Free Cash Flow stood at -$89.3 million in 2022, then climbed by 8.06% to -$82.1 million in 2023, then retreated by 4.0% to -$85.4 million in 2024, then grew by 18.72% to -$69.4 million in 2025, then plunged by 69.06% to -$117.3 million in 2026.
- Business Quant data shows NTLA's Free Cash Flow at -$117.3 million in Q1 2026, -$69.4 million in Q4 2025, and -$77.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - | -84.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -84.92 Mn |
| Jun 30, 2026 | -84.92 Mn |
| Mar 31, 2026 | -117.35 Mn |
| Mar 31, 2026 | -117.35 Mn |
| Dec 31, 2025 | -69.41 Mn |
| Dec 31, 2025 | -69.41 Mn |
| Sep 30, 2025 | -77.90 Mn |
| Sep 30, 2025 | -77.90 Mn |
| Jun 30, 2025 | -99.54 Mn |
| Jun 30, 2025 | -99.54 Mn |
| Mar 31, 2025 | -149.01 Mn |
| Mar 31, 2025 | -149.01 Mn |
| Dec 31, 2024 | -85.40 Mn |
| Dec 31, 2024 | -85.40 Mn |
| Sep 30, 2024 | -84.58 Mn |
| Sep 30, 2024 | -84.58 Mn |
| Jun 30, 2024 | -56.31 Mn |
| Jun 30, 2024 | -56.31 Mn |
| Mar 31, 2024 | -123.17 Mn |
| Mar 31, 2024 | -123.17 Mn |